Such findings have prompted research aimed at inhibiting HSD11B1 as a possible pharmacological target for the prevention of adverse metabolic profiles associated with glucocorticoid excess, such as Cushing syndrome, metabolic syndrome and obesity (Pereira et al., 2012; Morgan et al., 2014). The gene discussed is HSD11B1; the disease is Cushing syndrome.